O	0	10	Randomized
O	10	11	,
O	12	19	blinded
O	20	25	trial
O	26	28	of
B-intervention	29	36	vitamin
I-intervention	37	39	D3
O	40	43	for
O	44	52	treating
B-condition	53	62	aromatase
I-condition	63	72	inhibitor
I-condition	72	73	-
I-condition	73	83	associated
I-condition	84	99	musculoskeletal
I-condition	100	108	symptoms
I-condition	109	110	(
I-condition	110	115	AIMSS
I-condition	115	116	)
O	116	117	.

O	118	121	The
O	122	129	purpose
O	130	132	of
O	133	136	the
O	137	142	study
O	143	146	was
O	147	149	to
O	150	158	evaluate
O	159	162	the
O	163	171	efficacy
O	172	175	and
O	176	182	safety
O	183	185	of
O	186	193	vitamin
O	194	196	D3
O	197	199	at
O	200	204	4000
O	205	207	IU
O	207	208	/
O	208	211	day
O	212	214	as
O	215	216	a
O	217	226	treatment
O	227	233	option
O	234	237	for
O	238	247	aromatase
O	248	257	inhibitor
O	257	258	-
O	258	268	associated
O	269	284	musculoskeletal
O	285	293	symptoms
O	294	295	(
O	295	300	AIMSS
O	300	301	)
O	302	306	when
O	307	315	compared
O	316	320	with
O	321	324	the
B-control	325	330	usual
I-control	331	335	care
I-control	336	340	dose
O	341	343	of
O	344	347	600
O	348	350	IU
O	351	353	D3
O	353	354	.

O	355	357	We
O	358	367	conducted
O	368	369	a
O	370	376	single
O	377	381	site
O	382	392	randomized
O	392	393	,
O	394	400	double
O	400	401	-
O	401	406	blind
O	406	407	,
O	408	413	phase
O	414	415	3
O	416	424	clinical
O	425	430	trial
O	431	433	in
O	434	439	women
O	440	444	with
O	445	450	AIMSS
O	451	460	comparing
O	461	467	change
O	468	470	in
O	471	479	symptoms
O	479	480	,
O	481	493	reproductive
O	494	502	hormones
O	503	506	and
O	507	509	AI
O	510	526	pharmacokinetics
O	526	527	.

B-eligibility	528	542	Postmenopausal
I-eligibility	543	548	women
I-eligibility	549	550	≥
I-eligibility	550	552	18
I-eligibility	553	558	years
I-eligibility	559	563	with
I-eligibility	564	570	stages
I-eligibility	571	572	I
I-eligibility	572	573	-
I-eligibility	573	577	IIIA
I-eligibility	578	584	breast
I-eligibility	585	591	cancer
I-eligibility	591	592	,
I-eligibility	593	599	taking
I-eligibility	600	602	AI
I-eligibility	603	606	and
I-eligibility	607	619	experiencing
I-eligibility	620	625	AIMSS
I-eligibility	626	627	[
I-eligibility	627	633	breast
I-eligibility	634	640	cancer
I-eligibility	641	651	prevention
I-eligibility	652	657	trial
I-eligibility	658	665	symptom
I-eligibility	666	671	scale
I-eligibility	671	672	-
I-eligibility	672	687	musculoskeletal
I-eligibility	688	689	(
I-eligibility	689	693	BCPT
I-eligibility	693	694	-
I-eligibility	694	696	MS
I-eligibility	696	697	)
I-eligibility	698	706	subscale
I-eligibility	707	708	≥
I-eligibility	708	709	1
I-eligibility	709	710	.
I-eligibility	710	711	5
I-eligibility	711	712	]
O	713	717	were
O	718	726	admitted
O	726	727	.

O	728	737	Following
O	738	751	randomization
O	751	752	,
B-total-participants	753	756	116
O	757	765	patients
O	766	769	had
O	770	771	a
O	772	775	run
O	775	776	-
O	776	778	in
O	779	785	period
O	786	788	of
O	789	790	1
O	791	796	month
O	797	799	on
O	800	803	600
O	804	806	IU
O	807	809	D3
O	809	810	,
O	811	815	then
O	816	821	began
O	822	825	the
O	826	836	randomized
O	837	847	assignment
O	848	850	to
O	851	857	either
O	858	861	600
O	862	864	IU
O	865	867	D3
O	868	869	(
O	869	870	n
O	871	872	=
B-control-participants	873	875	56
O	875	876	)
O	877	879	or
O	880	884	4000
O	885	887	IU
O	888	890	D3
O	891	892	(
O	892	893	n
O	894	895	=
B-intervention-participants	896	898	57
O	898	899	)
O	900	905	daily
O	906	909	for
O	910	911	6
O	912	918	months
O	918	919	.

O	920	923	The
O	924	931	primary
O	932	940	endpoint
O	941	944	was
O	945	946	a
B-outcome-Measure	947	953	change
I-outcome-Measure	954	956	in
I-outcome-Measure	957	962	AIMSS
O	963	967	from
O	968	976	baseline
O	977	978	(
O	978	983	after
O	984	985	1
O	986	991	month
O	992	995	run
O	995	996	-
O	996	998	in
O	998	999	)
O	1000	1002	on
O	1003	1006	the
O	1007	1011	BCPT
O	1011	1012	-
O	1012	1014	MS
O	1015	1016	(
O	1016	1023	general
O	1024	1026	MS
O	1027	1031	pain
O	1031	1032	,
O	1033	1038	joint
O	1039	1043	pain
O	1043	1044	,
O	1045	1051	muscle
O	1052	1061	stiffness
O	1061	1062	,
O	1063	1068	range
O	1069	1072	for
O	1073	1077	each
O	1078	1086	question
O	1086	1087	:
O	1088	1089	0
O	1090	1091	=
O	1092	1095	not
O	1096	1098	at
O	1099	1102	all
O	1103	1105	to
O	1106	1107	4
O	1108	1109	=
O	1110	1119	extremely
O	1119	1120	)
O	1120	1121	.

O	1122	1128	Groups
O	1129	1132	had
O	1133	1135	no
O	1136	1149	statistically
O	1150	1161	significant
O	1162	1173	differences
O	1174	1189	demographically
O	1190	1192	or
O	1193	1203	clinically
O	1203	1204	.

O	1205	1210	There
O	1211	1215	were
O	1216	1218	no
O	1219	1230	discernable
O	1231	1242	differences
O	1243	1250	between
O	1251	1254	the
O	1255	1263	randomly
O	1264	1273	allocated
O	1274	1283	treatment
O	1284	1290	groups
O	1291	1293	at
O	1294	1295	6
O	1296	1302	months
O	1303	1305	in
B-outcome	1306	1314	measures
I-outcome	1315	1317	of
I-outcome	1318	1323	AIMSS
O	1323	1324	,
B-outcome	1325	1341	pharmacokinetics
I-outcome	1342	1344	of
I-outcome	1345	1356	anastrozole
I-outcome	1357	1360	and
I-outcome	1361	1370	letrozole
O	1370	1371	,
B-outcome	1372	1377	serum
I-outcome	1378	1384	levels
I-outcome	1385	1387	of
I-outcome	1388	1400	reproductive
I-outcome	1401	1409	hormones
O	1409	1410	,
O	1411	1413	or
B-outcome	1414	1421	adverse
I-outcome	1422	1428	events
O	1428	1429	.

O	1430	1432	We
O	1433	1438	found
O	1439	1441	no
O	1442	1453	significant
B-outcome	1454	1461	changes
I-outcome	1462	1464	in
I-outcome	1465	1470	AIMSS
I-outcome	1471	1479	measures
O	1480	1487	between
O	1488	1493	women
O	1494	1497	who
O	1498	1502	took
O	1503	1507	4000
O	1508	1510	IU
O	1511	1513	D3
O	1514	1519	daily
O	1520	1528	compared
O	1529	1533	with
O	1534	1537	600
O	1538	1540	IU
O	1541	1543	D3
O	1543	1544	.

O	1545	1548	The
O	1549	1553	4000
O	1554	1556	IU
O	1557	1559	D3
O	1560	1563	did
O	1564	1567	not
O	1568	1577	adversely
O	1578	1584	affect
O	1585	1597	reproductive
O	1598	1605	hormone
O	1606	1612	levels
O	1613	1615	or
O	1616	1619	the
O	1620	1626	steady
O	1627	1632	state
O	1633	1649	pharmacokinetics
O	1650	1652	of
O	1653	1664	anastrozole
O	1665	1667	or
O	1668	1677	letrozole
O	1677	1678	.

O	1679	1681	In
O	1682	1686	both
O	1687	1693	groups
O	1693	1694	,
O	1695	1700	serum
O	1701	1703	25
O	1703	1704	(
O	1704	1706	OH
O	1706	1707	)
O	1707	1708	D
O	1709	1717	remained
O	1718	1720	in
O	1721	1724	the
O	1725	1736	recommended
O	1737	1742	range
O	1743	1746	for
O	1747	1751	bone
O	1752	1758	health
O	1759	1760	(
O	1760	1761	≥
O	1761	1763	30
O	1764	1766	ng
O	1766	1767	/
O	1767	1769	mL
O	1769	1770	)
O	1771	1774	and
O	1775	1781	safety
O	1782	1783	(
O	1783	1784	<
O	1784	1786	50
O	1787	1789	ng
O	1789	1790	/
O	1790	1792	mL
O	1792	1793	)
O	1793	1794	.
